AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2225366 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 8012
Study 352974 — intervention group
Group type: EXPERIMENTAL
Intervention: melperone (Buronil)
Number of subjects: 60
Study 352974 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 352974 — intervention group
Group type: COMPARATOR
Intervention: melperone (Buronil) vs placebo
Number of subjects: 60
Study 31175903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 188
Study 31175903 — intervention group
Group type: COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Number of subjects: 188
Study 31175903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) for recurrent HCC
Number of subjects: 188
Study 28068365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 66
Study 28068365 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 66
Study 25530364 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (group B)
Number of subjects: 285
Study 25530364 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (group A)
Number of subjects: 285
Study 25530364 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (group C)
Number of subjects: 285
Study 23985260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (FP/H)
Number of subjects: 85
Study 23985260 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (FP)
Number of subjects: 85
Study 21624637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light disinfection of keyboards
Number of subjects: 0
Study 19417992 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouthrinse
Number of subjects: 82
Study 19417992 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 82
Study 16650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal application of 2% lidocaine gel
Number of subjects: 160
Study 16650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic anesthesia
Number of subjects: 160
Study 16650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of midazolam and meperidine
Number of subjects: 160
Study 16650294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedation or analgesic)
Number of subjects: 160
Study 15499296 — intervention group
Group type: COMPARATOR
Intervention: LR-RIT alone
Number of subjects: 73
Study 15499296 — intervention group
Group type: EXPERIMENTAL
Intervention: LR-RIT + TMZ
Number of subjects: 73
Study 11530870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (24 mg divided into 4 doses 12 hours apart)
Number of subjects: 139
Study 11530870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 139
Study 11367651 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingning Oral Liquid (QNOL) with conventional therapy, 10 ml three times a day for 30 days
Number of subjects: 40
Study 11367651 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 40
Study 8150234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-33 infusion (0.25 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Number of subjects: 14
Study 8150234 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin-33 infusion (0.5 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Number of subjects: 14
Study 8150234 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin-33 infusion (1.0 Ivy Dog Unit.kg‐1.h‐1) during hyperglycaemia
Number of subjects: 14
Study 2605963 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 2605963 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0
Study 2605963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1148091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blocks with lignocaine
Number of subjects: 138
Study 1148091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve blocks with bupivacaine
Number of subjects: 138
Study 1148091 — intervention group
Group type: COMPARATOR
Intervention: Control (no nerve block)
Number of subjects: 138
Study 30170956 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP-mesalamine (high exposure)
Number of subjects: 70
Study 30170956 — intervention group
Group type: COMPARATOR
Intervention: Non-DBP mesalamine (background exposure)
Number of subjects: 70
Study 28717811 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored nutrition plan with 3 telephone contacts and 1 home visit over 3 months (n = 52)
Number of subjects: 100
Study 28717811 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 100
Study 28717811 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and appetite measures
Number of subjects: 100
Study 26566122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemongrass oil hair tonic at 5%
Number of subjects: 30
Study 26566122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemongrass oil hair tonic at 10%
Number of subjects: 30
Study 26566122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemongrass oil hair tonic at 15%
Number of subjects: 30
Study 22617307 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics + Proxelan for 28 days
Number of subjects: 60
Study 22617307 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics for 28 days
Number of subjects: 60
Study 19863515 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exposure to DNCB 60 microg cm(‐2)
Number of subjects: 20
Study 19863515 — intervention group
Group type: COMPARATOR
Intervention: Three repeated exposures to DNCB 10 microg cm(‐2)
Number of subjects: 20
Study 18544384 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound infusion of 0.15% bupivacaine at 2 mL/h combined with intravenous patient-controlled analgesia
Number of subjects: 38
Study 18544384 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia alone with sham thoracotomy wound infusion of normal saline
Number of subjects: 38
Study 15793092 — intervention group
Group type: EXPERIMENTAL
Intervention: High tech softball bats with polyurethane softballs
Number of subjects: 7
Study 15793092 — intervention group
Group type: COMPARATOR
Intervention: Recommended safety standards
Number of subjects: 7
Study 12221310 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 150
Study 12221310 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Vocational Rehabilitation (EVR)
Number of subjects: 150
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: New antipsychotics (risperidone, olanzapine, sertindole, quetiapine)
Number of subjects: 2477
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: Sertindole and quetiapine
Number of subjects: 2477
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: Risperidone and olanzapine
Number of subjects: 2477
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: All new antipsychotics
Number of subjects: 2477
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2477
Study 9988841 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 2477
Study 7734250 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-corrected group
Number of subjects: 48
Study 7734250 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose group
Number of subjects: 48
Study 2341772 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study 2341772 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis
Number of subjects: 0
Study 6785797 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)deprenyl
Number of subjects: 0
Study 6785797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31590924 — intervention group
Group type: EXPERIMENTAL
Intervention: FAAH inhibitor (PF‐04457845, 4 mg orally, once daily)
Number of subjects: 45
Study 31590924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30935551 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft inflatable rubber ball (SIRB)
Number of subjects: 30
Study 30935551 — intervention group
Group type: COMPARATOR
Intervention: Hard massage ball (HMB)
Number of subjects: 30
Study 27940278 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 L/min via standard nasal prongs) during the 6-min walk test (6MWTO2)
Number of subjects: 124
Study 25661195 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7123 (30 mg, po, daily for 28 days)
Number of subjects: 18
Study 25661195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 23417515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 60 mg twice daily
Number of subjects: 12
Study 21795435 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (0.12 g · kg(‐1) · h(‐1))
Number of subjects: 20
Study 21795435 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study 21795435 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 20
Study 19376588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac
Number of subjects: 90
Study 19376588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 90
Study 19376588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19376588 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 17324660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba-based supplement (160 mg ginkgo biloba, 68 mg gotu kola, and 180 mg DHA per day for 4 months)
Number of subjects: 90
Study 17324660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16442038 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion extract gel (Mederma) applied three times daily for 8 weeks
Number of subjects: 24
Study 16442038 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based emollient (Aquaphor) applied three times daily for 8 weeks
Number of subjects: 24
Study 14673717 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented anterior lumbar interbody fusion (ALIF)
Number of subjects: 74
Study 14673717 — intervention group
Group type: COMPARATOR
Intervention: Instrumented circumferential fusion with PLIF
Number of subjects: 74
Study 11232592 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (500 IU/day, 8 days)
Number of subjects: 13
Study 11232592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 13
Study 11232592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9034695 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral (RUL) electroconvulsive therapy (ECT)
Number of subjects: 20
Study 1355427 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 16
Study 1355427 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 16
Study 1355427 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 1355427 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol (0.72 g.kg‐1, lean body mass)
Number of subjects: 16
Study 6438504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 124
Study 6438504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin
Number of subjects: 124
Study 6438504 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without initial angiography
Number of subjects: 124
Study 6438504 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal obstruction
Number of subjects: 124
Study 6438504 — intervention group
Group type: EXPERIMENTAL
Intervention: All four groups
Number of subjects: 124
Study 31618346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation (5 minutes in pressure-controlled ventilation mode, increasing pressure by 5cmH2O to a maximum of 35cmH2O)
Number of subjects: 38
Study 31618346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Number of subjects: 38
Study 31618346 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without changes in the parameters)
Number of subjects: 38
Study 30703315 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised consent form template
Number of subjects: 153
Study 30703315 — intervention group
Group type: COMPARATOR
Intervention: Original consent form template
Number of subjects: 153
Study 30703315 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about trials before reviewing consent forms
Number of subjects: 153
Study 30703315 — intervention group
Group type: COMPARATOR
Intervention: Revised and Original consent forms
Number of subjects: 153
Study 25628006 — intervention group
Group type: EXPERIMENTAL
Intervention: JDTic 1 mg
Number of subjects: 12
Study 25628006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25628006 — intervention group
Group type: EXPERIMENTAL
Intervention: JDTic
Number of subjects: 12
Study 25628006 — intervention group
Group type: COMPARATOR
Intervention: JDTic and Placebo
Number of subjects: 12
Study 23433414 — intervention group
Group type: COMPARATOR
Intervention: CT angiography
Number of subjects: 19
Study 23433414 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 19
Study 21731145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 24
Study 21731145 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 24
Study 21731145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask and Oronasal mask
Number of subjects: 24
Study 19372326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 66
Study 19372326 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based technique
Number of subjects: 66
Study 16885722 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 10 mg oral dose of dronabinol (synthetic THC)
Number of subjects: 18
Study 16885722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of THC (0.39, 0.47, and 14.8 mg THC in hemp oil and 7.5 mg dronabinol)
Number of subjects: 18
Study 16885722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models combined
Number of subjects: 18
Study 15595301 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) 0.2 g Cr x kg(‐1) after exercise
Number of subjects: 22
Study 15595301 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr)
Number of subjects: 22
Study 15595301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 11902516 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the European Randomised Study on Screening for Prostate Cancer
Number of subjects: 75000
Study 9404202 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 102
Study 9404202 — intervention group
Group type: COMPARATOR
Intervention: Citromag
Number of subjects: 102
Study 8390732 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with polymyxin E, tobramycin, and amphotericin B enterally and by oropharyngeal swab for 6 +/- 4 days
Number of subjects: 36
Study 8390732 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving perioperative parenteral antibiotics only
Number of subjects: 36
Study 8390732 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 36
Study 2427448 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% HES 200/0.5
Number of subjects: 55
Study 2427448 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 55
Study 31664632 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% Aloe Vera gel
Number of subjects: 140
Study 31664632 — intervention group
Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine gel
Number of subjects: 140
Study 30581291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA)-blocking drug
Number of subjects: 0
Study 30581291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28958469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (2.5 mg/day)
Number of subjects: 314
Study 28958469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.5 mg/day)
Number of subjects: 314
Study 26340002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 285
Study 24734355 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours Chlorhexidine (CHX) 0.5% oral decontamination
Number of subjects: 30
Study 24734355 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours Chlorhexidine (CHX) 0.5% oral decontamination
Number of subjects: 30
Study 22014804 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler guided fluid
Number of subjects: 66
Study 18000094 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily of micronized DHEA
Number of subjects: 106
Study 18000094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 17095898 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate alone
Number of subjects: 54
Study 17095898 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate plus nitrazepam and/or valproate
Number of subjects: 54
Study 17095898 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (average dosage 5.2 mg/kg per day)
Number of subjects: 54
Study 12907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Number of subjects: 549
Study 12907482 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable heroin plus methadone (maximum 1000 mg heroin per day and 150 mg methadone per day)
Number of subjects: 549
Study 12907482 — intervention group
Group type: COMPARATOR
Intervention: Methadone alone (maximum 150 mg per day)
Number of subjects: 549
Study 12796135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 389
Study 12796135 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 389
Study 10766402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 0
Study 10766402 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty and coronary artery bypass grafting
Number of subjects: 0
Study 8682597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60-90 mg o.d.
Number of subjects: 339
Study 8682597 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate 40-60 mg b.d.
Number of subjects: 339
Study 8682597 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate 50-100 mg o.d.
Number of subjects: 339
Study 1992535 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (320 to 1,600 mg/d)
Number of subjects: 0
Study 1992535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6522192 — intervention group
Group type: EXPERIMENTAL
Intervention: Free social interaction (interactive condition)
Number of subjects: 72
Study 6522192 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting expectancy (expected waiting)
Number of subjects: 72
Study 6522192 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive conditions
Number of subjects: 72
Study 31620886 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (10 mg)
Number of subjects: 100
Study 31620886 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 100
Study 29096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated physical activity (task relevant)
Number of subjects: 120
Study 29096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintegrated physical activity (task nonrelevant)
Number of subjects: 120
Study 29096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing integrated physical activity
Number of subjects: 120
Study 29096234 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedentary teaching
Number of subjects: 120
Study 27491669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 4
Study 27491669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation using a total body recumbent stepper (TBRS)
Number of subjects: 4
Study 27491669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Tai Chi and TBRS
Number of subjects: 4
Study 27491669 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4
Study 24857206 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE regimen (pirarubicin + cytarabine + etoposide)
Number of subjects: 56
Study 24857206 — intervention group
Group type: COMPARATOR
Intervention: MAE regimen (mitoxantrone + cytarabine + etoposide)
Number of subjects: 56
Study 22784345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger combination (340 mg EV.EXT 35 Zingiber officinalis extract)
Number of subjects: 43
Study 22784345 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 mg daily)
Number of subjects: 43
Study 22784345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ginger and diclofenac)
Number of subjects: 43
Study 20357732 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobials (cefuroxim, ceftibuten, and others) for 5 days
Number of subjects: 9
Study 20357732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 20357732 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril and enalapril)
Number of subjects: 9
Study 20357732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressants for crescentic poststreptococcal glomerulonephritis
Number of subjects: 9
Study 17509728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-carbohydrate (HPLC) diet
Number of subjects: 25
Study 17509728 — intervention group
Group type: COMPARATOR
Intervention: Low-protein high-carbohydrate (LPHC) diet
Number of subjects: 25